Ohio State University Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).
Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.
Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.
Top-decile sponsor footprint
Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
341 total, page 1 of 7
Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants
NCT07216534
Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial
NCT07584239
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
NCT06741072
Comparative Evaluation of Nicotine Analogs
NCT07585006
Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms
NCT07529483
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
NCT07609030
A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer
NCT07447700
Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women
NCT07320664
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
NCT07619391
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
NCT07144826
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
NCT06424522
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
NCT07407647
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
NCT07474519
A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer
NCT07455513
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
NCT07386444
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
NCT07166419
Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
NCT07215988
Strategies for Optimizing a Mailed FIT Program in Appalachia
NCT07173985
Living Well With Advanced Breast Cancer
NCT07227038
A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
NCT06950008
A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
NCT07124611
Spine Oncology Registry
NCT07225491
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
NCT06391099
Examining Heavy Metal Exposure and Respiratory Health in Young Adult Electronic Cigarette Users
NCT07215065
Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences
NCT07111234
Studying the Effects of Nicotine Concentration and Flavor on Alcohol Use in Young Adults
NCT07095140
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
NCT07341503
Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia
NCT06763536
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
NCT06964737
Studying the Health Perceptions and Social Behaviors of Graduate Students at the Ohio State University for the Development of Effective Oral Nicotine Pouch Addictive Risk Communication
NCT07346092
Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery
NCT06949943
Daance FOR Chemotherapy-induced Neuropathy
NCT06749210
Addiction Potential of Very Low Nicotine Filtered Little Cigars
NCT06630728
Informing Oral Nicotine Pouch Regulations to Promote Public Health
NCT06315881
Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff
NCT06249984
Online Tai Chi Intervention to Promote Smoking Cessation Among Cancer Survivors
NCT05941858
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT06582615
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women
NCT06635005
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
NCT06500065
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805
Manipulating E-Cigarette Nicotine to Promote Public Health
NCT06448351
Perceptions of E-Cigarettes and Synthetic Cooling Agents, The ICE Study
NCT06208202
Designing a Dyad-Based MHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers
NCT06746012
A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior
NCT06260683
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
NCT06323460
The Ohio State University (OSU) SCREEN Community Program
NCT06666192
Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior
NCT06192316
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
NCT06396598
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
NCT06223659
Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT05193149
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 59 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Ohio State University Comprehensive Cancer Center pipeline
77 recruiting of 341 indexed (23% open); 206 completed (60%).
Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).
Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 341 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
Sponsors near 23% open enrollment (± trial volume)
- University of Delaware · 23% recruiting · 106 trials
- University of Virginia · 22% recruiting · 449 trials
- University of Kansas Medical Center · 23% recruiting · 408 trials
- University of Oklahoma · 22% recruiting · 358 trials
Related
What to do with this Ohio State University Comprehensive Cancer Center page
341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.
- 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.